Comparison

AbbVie Inc. (ABBV) vs TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

ABBV

AbbVie Inc.

Drug Manufacturers—General

Revenue, FY25: $61.16B
Net income: $4.23B
Operating cash flow: $19.03B
Free cash flow: $17.82B
Net margin: 6.91%
Operating margin: 24.65%
Gross margin: 70.24%

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD

Drug Manufacturers—Specialty & Generic

Revenue, FY25: $17.26B
Net income: $1.41B
Operating cash flow: $1.65B
Free cash flow: -
Net margin: 8.17%
Operating margin: 12.50%
Gross margin: 51.79%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	ABBV	TEVA
Revenue growth, latest filed year	+8.57%	+4.32%
Piotroski F-score	8 of 9	7 of 8
P/E against its own history	54.65% above	-

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

ABBV

Reimbursement
Goodwill impairment
Litigation
Product recalls
FDA approval
Supply chain

And 16 more.

TEVA

No 10-K read yet.

Tracked managers holding both

No manager tracked here reports a position in both, as of each company’s latest filed 13F.

Updated Sep 16, 2026 · the newer of the two companies' filings